March 25, 2026
MSD and Quotient collaborate on IBD drug targets
Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory bowel disease (IBD) using the latter’s somatic genomics platform technology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







